Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
PRGO [NYSE]
Perrigo Company Public Limited Company
IndexS&P 500 P/E75.05 EPS (ttm)2.57 Insider Own0.10% Shs Outstand140.78M Perf Week-3.06%
Market Cap27.16B Forward P/E22.65 EPS next Y8.52 Insider Trans-13.57% Shs Float140.08M Perf Month18.33%
Income346.50M PEG6.25 EPS next Q1.78 Inst Own78.00% Short Float1.85% Perf Quarter22.96%
Sales4.17B P/S6.51 EPS this Y-62.00% Inst Trans-0.83% Short Ratio1.48 Perf Half Y28.56%
Book/sh71.28 P/B2.71 EPS next Y16.88% ROA2.40% Target Price187.30 Perf Year30.98%
Cash/sh25.69 P/C7.51 EPS next 5Y12.00% ROE3.90% 52W Range125.00 - 215.73 Perf YTD15.49%
Dividend0.50 P/FCF36.60 EPS past 5Y3.10% ROI2.80% 52W High-10.59% Beta0.26
Dividend %0.26% Quick Ratio3.60 Sales past 5Y15.20% Gross Margin34.40% 52W Low54.31% ATR6.78
Employees10220 Current Ratio4.00 Sales Q/Q-44.00% Oper. Margin15.70% RSI (14)58.59 Volatility3.25% 3.99%
OptionableYes Debt/Eq0.49 EPS Q/Q96.20% Profit Margin8.30% Rel Volume4.69 Prev Close201.63
ShortableYes LT Debt/Eq0.46 EarningsMay 06 BMO Payout16.20% Avg Volume1.75M Price192.89
Recom2.00 SMA203.86% SMA5013.54% SMA20022.31% Volume8,218,780 Change-4.33%
Apr-22-15Reiterated B. Riley & Co. Buy $189 → $195
Apr-10-15Downgrade Argus Buy → Hold
Feb-06-15Reiterated RBC Capital Mkts Outperform $177 → $175
Nov-12-14Reiterated Argus Buy $160 → $175
Nov-07-14Reiterated RBC Capital Mkts Outperform $169 → $177
Sep-22-14Reiterated RBC Capital Mkts Outperform $160 → $169
May-15-14Reiterated Argus Buy $175 → $160
May-08-14Reiterated B. Riley & Co. Neutral $170 → $157
May-08-14Downgrade RBC Capital Mkts Top Pick → Outperform $187 → $160
Mar-03-14Reiterated UBS Buy $176 → $190
Mar-03-14Reiterated Stifel Buy $165 → $175
Feb-25-14Reiterated CRT Capital Buy $165 → $175
Feb-07-14Downgrade B. Riley & Co. Buy → Neutral
Jan-16-14Reiterated Argus Buy $160 → $175
Jan-07-14Initiated RBC Capital Mkts Top Pick $187
Dec-12-13Reiterated Stifel Buy $150 → $165
Nov-07-13Reiterated Argus Buy $152 → $160
Nov-04-13Reiterated UBS Buy $140 → $160
Oct-21-13Initiated Argus Buy $152
Sep-17-13Initiated CRT Capital Buy $145
Apr-24-15 05:51PM  Mylan 'Raises' Perrigo Bid, But Teva Buzz Builds at Investor's Business Daily
05:03PM  Mylan makes official bid for Perrigo in generic drug contest
04:06PM  Mylan Inc. -- Moody's: Mylan's Offer for Perrigo Credit Negative but Could be Investment Grade at Moody's
04:05PM  Raised Bid in Three-Way Generic Drug Takeover Battle at The Wall Street Journal
04:00PM  Techs surge on earnings, boosts Nasdaq, S&P 500 to record close at CNBC
03:41PM  Perrigo (PRGO) Stock Declines Today After Rejecting Second Mylan Bid This Week at TheStreet
03:18PM  Deutsche Bank Boosts Mylan's Price Target On This Scenario
01:16PM  Mylan/Perrigo, a more likely combination: Pro
12:46PM  Perrigo rejects formal Mylan takeover offer at Financial Times
12:43PM  $32B deal: Mylan boosts offer for drugmaker Perrigo at USA TODAY
12:28PM  Perrigo Rejects Mylan Unsolicited Offer at noodls
12:09PM  Perrigo Rejects Mylan Unsolicited Offer PR Newswire
11:49AM  Mylan tries to fend off Teva with bigger bid for Perrigo at MarketWatch
11:44AM  Mylan's Formal Offer For Perrigo Will Heat Up Pharma Dealmaking at Forbes
11:35AM  Mylan makes formal bid for Perrigo at bizjournals.com
11:03AM  Perrigo (PRGO) Stock Falls Today After Receiving $33 Billion Takeover Offer From Mylan at TheStreet
10:37AM  Mylan lowers price for Perrigo
10:23AM  Mylan ups the ante for Perrigo with $33 billion bid at MarketWatch
10:20AM  Mylan says to commence offer for Perrigo Reuters
10:02AM  Mylan To Commence Formal Offer To Acquire Perrigo For US$60 In Cash And 2.2 Mylan Shares Per Perrigo Share at noodls
09:44AM  Mylan To Commence Formal Offer To Acquire Perrigo For US$60 In Cash And 2.2 Mylan Shares Per Perrigo Share PR Newswire
06:51AM  Epic battles brewing in pharma space
Apr-23-15 03:55PM  Dealpolitik: Three Ways to Look at the Three-Way Pharma Scrum at The Wall Street Journal
02:01PM  What Are the Conditions of the Mylan-Teva Deal?
Apr-22-15 08:17PM  Mylan readies its poison pill defences at Financial Times
05:02PM  Mylan Should Either Find A Friendly Suitor Or Negotiate A Better Deal With Teva at Forbes
02:11PM  Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
02:09PM  The love-hate triangle in pharma
01:38PM  Perrigo Announces The Launch Of A Generic Version Of Kenalog® Topical Spray at noodls
01:18PM  Perrigo (PRGO) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
11:59AM  Analyst Finds Perrigo 'Still Attractive' As Take Out Target
11:51AM  What's Gabelli Saying About Teva Now?
11:30AM  Mylan may be planning new offer for Perrigo at bizjournals.com
10:00AM  Mylan plans to make new offer for Perrigo - CNBC Reuters
09:00AM  Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog
08:45AM  Five things to know today, and a big reason you want to check your Google search history, fast at bizjournals.com
08:34AM  Goldman Sachs's Mylan Connection at The Wall Street Journal
Apr-21-15 08:50PM  Mylan Inc. -- Moody's Affirms Mylan's Baa3; outlook changed to developing at Moody's
05:26PM  Perrigo takes 3Q loss, says it won't take Mylan's $29B bid
05:00PM  Perrigo Company plc Reports Record Fiscal Third Quarter Net Sales, Adjusted Net Income, Adjusted Margins, And Operating Cash Flow at noodls
05:00PM  Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan at noodls
04:56PM  Two Stocks Stand Out In Red-Hot But Volatile Biotech Sector at Forbes
04:26PM  Perrigo rejects $205/share bid from Mylan Reuters
04:25PM  Perrigo rejects Mylan bid of $205 a share at MarketWatch
04:06PM  Perrigo rejects Mylan's bid
04:03PM  Perrigo Company plc Reports Record Fiscal Third Quarter Net Sales, Adjusted Net Income, Adjusted Margins, And Operating Cash Flow PR Newswire
04:01PM  Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan PR Newswire
03:30PM  Biotech buyout? Teva's $40 billion bid
03:08PM  Teva's $40 Billion Bid for Mylan a Winner at Barrons.com
01:50PM  Teva makes unsolicited $40B offer for rival generic drug maker at bizjournals.com
01:27PM  Teva/Mylan: Brand management at Financial Times
12:36PM  Investors wary of Teva-Mylan merger at MarketWatch
12:35PM  Time to take profits in biotech?
12:01PM  Mylan's Stock Pops, Perrigo's Drops on Teva Bid at The Wall Street Journal
10:52AM  Mylan Shares Jump On $40 Billion Bid From Teva Pharmaceutical
10:19AM  Teva Pharmaceuticals Hopes $40 Billion Mylan Deal Will Fuel Stock Rebound at Forbes
10:09AM  Israel's Teva offers $40.1bn for US drugmaker Mylan at Financial Times
09:50AM  Why Teva Really Wants to Acquire Mylan at 24/7 Wall St.
09:50AM  Teva makes unsolicited $82-a-share offer for Mylan at bizjournals.com
09:42AM  Generic drugmaker Teva makes $40 billion offer for rival Mylan Reuters
09:17AM  Teva Offers $82 A Share For Mylan; Stocks Rise at Investor's Business Daily
09:01AM  Teva makes bid for Mylan
07:11AM  Teva declines to comment on report it to make offer for Mylan Reuters
Apr-20-15 04:08PM  MylanPerrigo Merger: What Are the Long-Term Growth Drivers?
08:50AM  Perrigo Animal Health Encourages Americans to Honor K-9 Officers During Second Annual "National Thank a Police Dog Week" at noodls
08:38AM  Perrigo Animal Health Encourages Americans to Honor K-9 Officers During Second Annual "National Thank a Police Dog Week" PR Newswire
Apr-17-15 04:28PM  It was a day to forget on Wall Street...
03:31PM  Mylan says merger with Teva would be bad fit
03:17PM  Mylan: There's No Logic In The Teva Merger Rumor
02:58PM  Mylan to Teva: Thanks but no thanks, we'll stay independent at bizjournals.com
02:50PM  Mylan: Fully committed to stand alone strategy
02:37PM  Teva considering potential bid for Mylan - Bloomberg
02:31PM  Teva considering bid for Mylan: Report at CNBC
02:25PM  Teva considering bid for Mylan: DJ
Apr-16-15 02:24PM  Perrigo Announces The Launch Of A Generic Version Of Kenalog® Nasal Spray at noodls
02:10PM  Perrigo Announces The Launch Of A Generic Version Of Kenalog® Nasal Spray PR Newswire
08:45AM  Global Pharma Company Mylan Offers to Buy Perrigo
Apr-15-15 03:52PM  Bucking The Trend With Pattern Failure Strategies at Investopedia
Apr-13-15 11:05PM  Magnetar Capital Raises Its Stake in Actavis
07:16PM  Cramer Remix: This is what I think of Netflix at CNBC
03:25PM  Mylan Notifies Perrigo of HSR Filing Regarding Proposed Acquisition at noodls
02:11PM  Pharma ETFs Soar on Acquisition Spree - ETF News And Commentary
01:43PM  Why The Mylan 'Love Triangle' Could Benefit Investors
06:45AM  Mylan Notifies Perrigo of HSR Filing Regarding Proposed Acquisition PR Newswire
Apr-12-15 09:50PM  The presidency, #ImNoAngel and a $29B acquisition are on the minds of our women to watch this week at bizjournals.com
08:52PM  MoneyBeat: Big Deals Are a Big Deal at The Wall Street Journal
Apr-09-15 06:25PM  Specialty pharma; remember those two words: Cramer
06:00PM  Cramer: Invest in best of breed
05:10PM  Gap shares decline as sales fall at namesake store at MarketWatch
02:40PM  Should Mylan Marry Perrigo Or Teva? Street Debates at Investor's Business Daily
02:26PM  Top trades to go before Thursday's close at CNBC
12:02PM  Altera tumbles as Intel walks away; Zynga changes trigger selling
11:32AM  1 Challenge Bank Of America Sees For Mylan And Perrigo
10:50AM  Mylan Proposes to Acquire Perrigo, Sets Both Stocks Soaring - Analyst Blog
10:40AM  Everything is up for grabs in pharmaceuticals: Pro
10:37AM  The Winner In A Mylan-Perrigo Deal? Teva, Says Citi at Barrons.com
09:44AM  Faber Report: Mylan to buy Perrigo
08:52AM  Cramer's stocks to watch: Perrigo & Mylan
08:07AM  U.S. stocks: Futures waver as investors digest Fed minutes, earnings at MarketWatch
07:00AM  Jim Cramer -- Mylan's Move to Acquire Perrigo a Prescription for Success at TheStreet
Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company's Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company's API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Option Exercise107.058,800941,9974,148Apr 16 04:14 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Sale200.278,8001,762,3760Apr 16 04:14 PM
KINGMA TODD WExecutive VP, General CounselApr 13Option Exercise35.851,30046,60510,664Apr 15 02:57 PM
KINGMA TODD WExecutive VP, General CounselApr 13Sale198.441,300257,9729,364Apr 15 02:57 PM
Shah JatinSr VP & Chief Scientific OfficMar 13Sale165.502,000331,0003,291Mar 17 10:50 AM
Yu LouisExecutive VP Global QualityMar 12Sale166.2714023,2784,746Mar 16 04:35 PM
Farrington ThomasSenior VP and CIOFeb 20Sale151.1851778,161321Feb 24 04:26 PM
Farrington ThomasSenior VP and CIOFeb 06Option Exercise0.0079801,119Feb 09 04:37 PM
MORRIS HERMAN JRDirectorNov 14Sale154.4220030,8831,400Nov 17 05:22 PM
Kochan SharonEVP, GM InternationalNov 10Option Exercise90.655,367486,51910,767Nov 12 04:37 PM
Kochan SharonEVP, GM InternationalNov 10Sale156.365,367839,1845,400Nov 12 04:37 PM
Yu LouisExecutive VP Global QualityNov 10Sale155.1125940,1734,886Nov 12 04:33 PM
Brown Judy LExecutive VP & CFONov 03Option Exercise48.923,515171,9539,445Nov 05 04:39 PM
Brown Judy LExecutive VP & CFONov 03Sale160.603,515564,5077,445Nov 05 04:39 PM
Brown Judy LExecutive VP & CFOOct 01Option Exercise48.923,515171,9539,445Oct 02 04:26 PM
Brown Judy LExecutive VP & CFOOct 01Sale150.723,515529,7817,445Oct 02 04:26 PM
KINGMA TODD WExecutive VP, General CounselSep 03Sale150.101,000150,0952,000Sep 03 05:00 PM
Kochan SharonEVP, GM InternationalSep 03Sale150.001,116167,4005,400Sep 04 04:42 PM
Farrington ThomasSenior VP and CIOSep 02Sale150.361,741261,773321Sep 03 05:12 PM
KINGMA TODD WExecutive VP, General CounselAug 29Option Exercise35.851,25044,81310,614Sep 03 05:00 PM
KINGMA TODD WExecutive VP, General CounselAug 29Sale149.301,250186,6259,364Sep 03 05:00 PM